BillionToOne, Inc.
NASDAQ:BLLNMedical - Diagnostics & Research
+$0.84 today
- Market cap
- $4.37B
- Beta
- 0.90
- P/E (TTM)
- 182.6
- EPS (TTM)
- $0.55
Volume 1.44M
Average 0.59M
BLLN Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
BillionToOne, Inc.NASDAQ: BLLN
Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Investing cash flow turns negative
Q2 FY2026 investing cash flow was -$4.05M, compared with $0 a year earlier. Trailing-twelve-month investing cash flow was -$12.22M.
Context
- Investing cash flow amounted to 2.9% of revenue in FY2025, down 0.6 pp from a year earlier.
- Investing cash flow increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near -$4.05M or moves back toward the trailing-twelve-month quarterly average of -$3.06M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (8.92M) USD
- Year-over-year change
- -64.2%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.92M) | -64.2% |
| FY2024 | 2024-12-31 | (5.43M) | -106.6% |
| FY2023 | 2023-12-31 | 82.84M | — |
Investing Cash Flow vs competitors
How BLLN compares with its peers on the latest reported figures
- BLLN's LTM Jun 2026 investing cash flow of $12.22M is the smallest of the 9 companies compared; the peer median is $68.66M.
- Investing cash flow amounts to 3.1% of revenue for BLLN, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $310.04M | -32.9% | +55.0% | 187.6% | |
| LTM Jun 2026 | $187.06M | +1913.6% | — | 6.9% | |
| LTM Sep 2026 | $117.66M | -140.8% | — | 9.2% | |
| LTM Jun 2026 | $98.67M | -9.0% | -32.1% | 17.6% | |
| LTM Mar 2026 | $94.58M | +471.0% | — | 29.5% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $38.64M | -28.5% | -24.2% | 8.5% |
| LTM Mar 2026 | $25.6M | +95.4% | -29.3% | 3.1% | |
| LTM Jun 2026 | $19.9M | +35.0% | — | 2.6% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.22M | — | — | 3.1% |
| Peer median (excluding BLLN) | $68.66M | +13.0% | -26.8% | 8.9% | |
Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (82.68M) | (41.57M) | 2.92M |
| Depreciation & Amortization | 6.46M | 11.69M | 11.91M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 4.85M | 8.36M | 15.92M |
| Change in Working Capital | 3.79M | (16.77M) | (22.05M) |
| Accounts Receivables | (2.59M) | (15.62M) | (16.91M) |
| Inventory | (1.41M) | (1.54M) | (8.81M) |
| Accounts Payables | 151K | 877K | 1.78M |
| Other Working Capital | 7.64M | (489K) | 1.89M |
| Other Non-Cash Items | 13.9M | (3.09M) | 15.91M |
| Operating Cash Flow | (53.67M) | (41.38M) | 24.6M |
| Capital Expenditures | (6.17M) | (5.4M) | (8.88M) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 90M | 0 | 0 |
| Other Investing Activities | (988K) | (31K) | 0 |
| Investing Cash Flow | 82.84M | (5.43M) | (8.92M) |
| Debt Repayment | 12.96M | 10.48M | (1.73M) |
| Common Stock Issued | 444K | 131.08M | 290.55M |
| Common Stock Repurchased | 0 | (546K) | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 13.41M | 141.02M | 288.83M |
| Effect of Forex Changes | 54.7M | 0 | 0 |
| Net Change in Cash | 97.27M | 94.21M | 304.5M |
| Free Cash Flow | (59.85M) | (46.78M) | 15.71M |
BillionToOne, Inc.
NASDAQ:BLLN
Intrinsic Alpha fair value
Locked
Current Price
$91.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.